by GlobeNewsWire | Mar 10, 2016 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2015. Loss from operations for the three months and year ended December...
by GlobeNewsWire | Dec 21, 2015 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of underwritten offerings of (i) 10,996,191 shares of its common stock, that included the exercise of the underwriter’s...
by GlobeNewsWire | Dec 16, 2015 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten offerings of (i) 9,561,905 shares of its common stock at a price of $0.84 per share, and (ii) 20,200 shares of...
by GlobeNewsWire | Dec 3, 2015 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it has initiated a Compassionate Use Program for vosaroxin. The Compassionate Use Program will be made available to eligible patients in...
by GlobeNewsWire | Dec 1, 2015 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been treated in an investigator-sponsored pilot study of vosaroxin and cytarabine in adult patients age 60 years...